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Hypoxia-inducible transcription factors (HIFs) con-
trol adaptation to low oxygen environments by acti-
vating genes involved in metabolism, angiogenesis,
and redox homeostasis. The finding that HIFs are
also regulated by small molecule metabolites high-
lights the need to understand the complexity of their
cellular regulation. Here we use a forward genetic
screen in near-haploid human cells to identify genes
that stabilize HIFs under aerobic conditions. We
identify twomitochondrial genes, oxoglutarate dehy-
drogenase (OGDH) and lipoic acid synthase (LIAS),
whichwhenmutated stabilize HIF1a in a non-hydrox-
ylated form. Disruption of OGDH complex activity in
OGDH or LIAS mutants promotes L-2-hydroxygluta-
rate formation, which inhibits the activity of the HIFa
prolyl hydroxylases (PHDs) and TET 2-oxoglutarate
dependent dioxygenases. We also find that PHD ac-
tivity is decreased in patients with homozygous
germline mutations in lipoic acid synthesis, leading
to HIF1 activation. Thus, mutations affecting OGDHC
activity may have broad implications for epigenetic
regulation and tumorigenesis.
INTRODUCTION
Hypoxia-inducible transcription factors (HIFs) are central to the
metazoan hypoxia response and are key mediators of glycol-
ysis, regulating approximately 600 genes to promote cell
survival in low oxygen tensions (Benita et al., 2009; Manalo
et al., 2005). Undesirable consequences of their activation
can promote tumor formation, lead to the development of pul-
monary hypertension, and result in altered immune responses
(Kaelin, 2008; Maxwell and Ratcliffe, 2002). Therefore, under-
standing how HIFs are regulated is of fundamental biological
importance.740 Cell Metabolism 25, 740–752, November 8, 2016 ª 2016 The Au
This is an open access article under the CC BY license (http://creativeThe principal mechanism for regulating HIFs relies on constitu-
tive hydroxylation and ubiquitin-mediated proteasomal degra-
dation of the HIFa subunit in aerobic conditions, which prevents
the formation of an active heterodimeric transcription factor
with HIFb (aryl hydrocarbon receptor nuclear translocator
[ARNT]). Prolyl hydroxylase domain enzymes (PHDs) act as
oxygen sensors within cells and hydroxylate HIFa at two
conserved proline residues within its oxygen-dependent degra-
dation domain (ODD) (Bruick and McKnight, 2001; Epstein
et al., 2001). This hydroxylation signals the recruitment of the
Von Hippel (pVHL) ubiquitin E3 ligase complex (Maxwell
et al., 1999) and the subsequent proteasomal degradation of
HIFa. As PHDs are members of the 2-oxoglutarate- (2-OG, or
a-ketoglutarate) dependent dioxygenase family, which requires
oxygen and 2-OG for catalytic activity, they are also highly
sensitive to alterations in levels of 2-OG or other tricarboxylic
acid (TCA) cycle intermediates (Hewitson et al., 2007). HIF
levels are therefore likely to be regulated by a complex interplay
between oxygen and metabolic signals, which are not fully
understood.
Here, we use a forward genetic screen in near-haploid human
cells to take an unbiased approach to identify genes that regu-
late HIF1a (themost widely expressed form of HIF) under aerobic
conditions. This type of genetic approach had been restricted to
yeast, due to the difficulty in generating bi-allelic mutations in hu-
man cells, but was recently circumvented with the generation of
the near-haploid human KBM7 cell line (karyotype 25, XY, +8,
Ph+), which has been used successfully to identify host restric-
tion factors for pathogens (Carette et al., 2009) and epigenetic
regulators (Tchasovnikarova et al., 2015). Using a gene-trap
mutagenesis screen in KBM7 cells expressing a sensitive fluo-
rescent HIF1a reporter, we not only identify genes involved in
the canonical regulation of HIFs (VHL and PHD2), but also iden-
tify two conserved mitochondrial genes, oxoglutarate dehydro-
genase (OGDH) and lipoic acid synthase (LIAS), which stabilize
HIF1a by preventing its prolyl hydroxylation. Both enzymes are
required for correct functioning of the OGDH complex (OGDHC),
and disruption of this complex stabilizes HIF1a by conversion
of 2-OG to L-2-hydroxyglutarate (L-2-HG). Our studies place
OGDHC activity central to HIF1a regulation in aerobic conditionsthor(s). Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
Figure 1. A Human Forward Genetic Screen
Identifies OGDH and LIAS as Regulators of
HIF1a Stability
(A) Schematic of the HIF1a-GFPODD reporter
construct.
(B and C) KBM7 cells expressing the HIF1a-
GFPODD reporter were incubated in 21% or 1%
oxygen for 24 hr. The cells incubated in 1% oxy-
gen were then exposed to 21% oxygen for 24 hr
(reoxygenation). GFP levels were measured by
flow cytometry (B) and HIF1a levels by immuno-
blot (C).
(D) KBM7 forward genetic screen with a HIF1a-
GFPODD expressing clone. The cells were muta-
genized with the Z-loxP-mCherry gene-trap
retrovirus, enriched for GFPHIGH cells by FACS,
and insertion sites identified by HiSeq Illumina
sequencing.
(E) Bubble plot of enriched genes in the GFPHIGH
population compared to unsorted mutagenized
control KBM7 HIF1a-GFPODD cells. Bubble size is
proportional to the number of independent in-
activating gene-trap integrations identified (shown
in brackets). Genes that were significantly en-
riched (>-log(p) 4) and that were successfully
validated by CRISPR-Cas9 deletion in HeLa
HIF1a-GFPODD reporter cells are highlighted in
green. Four genes (IWS1, ZCCHC11, CRAMP1L,
and WHSC2) were enriched for gene-trap in-
sertions but did not pass validation in HeLa
HIF1a-GFPODD reporter cells.
(F) Location of the enriched gene-trap insertions in
the OGDH, LIAS, VHL, and PHD2 genes (red,
sense insertion; blue, anti-sense insertion). The
predominance of insertions in the correct orien-
tation at the start of the gene indicates enrichment
for gene-trapping mutations.
(G) Structure of the OGDH complex (OGDH, DLST,
and DLD subunits), showing the region of lip-
oylation on DLST and its rotation depending on
redox cycling by DLD (see also Figure S3B).
(H) Validation of the screen using CRISPR-Cas9-
targeted depletion (sgRNA) of PHD2, VHL, OGDH,
and LIAS in HeLa HIF1a-GFPODD reporter cells.
Two sgRNAs were used for depletion of OGDH
and LIAS. GFP reporter levels were measured by
flow cytometry. See also Figure S1.and provide the first evidence that defects in lipoic acid synthesis
affect PHD activity.
RESULTS
A KBM7 Forward Genetic Screen Identifies OGDH and
LIAS as Regulators of HIFa Stability
Wefirst developed a sensitive HIF1a reporter for use in the KBM7
forward genetic screen that would reflect the kinetics of endog-
enous HIF1a stability. A fluorescent construct, consisting of GFP
fused with amino acids 530–603 of the HIF1a ODD, was ex-
pressed under the control of a minimal HIF-responsive element
(HRE) promoter, forming a reporter (HIF1a-GFPODD) that could
be induced and degraded in a HIF1a-dependent manner (Fig-
ure 1A). The specificity of this reporter was confirmed in KBM7
and HeLa cells lentivirally transduced with the HIF1a-GFPODDconstruct. GFP fluorescence was low in cells incubated at
21% oxygen but increased concurrently with HIF1a stabilization
when cells were either exposed to hypoxia (1% oxygen) or
treated with the PHD inhibitor, dimethyl oxaloylglycine (DMOG)
(Figures 1B, 1C, and S1A–S1D). Removing HIF1a-GFPODD cells
from 1% oxygen and re-incubating them at 21% oxygen
restored endogenous HIF1a degradation and returned GFP fluo-
rescence to basal levels, thereby confirming that GFP correlated
with endogenous HIF1a stability (Figures 1B and 1C). We also
ensured that KBM7 cells showed a HIF1a transcriptional
response by examining the hypoxic induction of vascular endo-
thelial growth factor (VEGF) and Carbonic Anhydrase 9 (CA9)
(Figures S1E and S1F).
We screened for genes that stabilize HIF1a by randomly muta-
genizing clonal KBM7 HIF1a-GFPODD reporter cells with a gene-
trapping retrovirus (Figure S1G) and enriching for the rareCell Metabolism 25, 740–752, November 8, 2016 741
GFPHIGH cells by a single round of sequential fluorescence-acti-
vated cell sorting (FACS) after 8 days (Figure 1D). By mapping
gene-trap insertion sites in the GFPHIGH population compared
to non-mutagenized controls, we identified several genes that
were enriched for inactivating insertions (Figure 1E). We then
validated genes identified in the screen using clustered regularly
interspaced short palindromic repeats (CRISPR)-Cas9-targeted
deletions in HIF1a-GFPODD reporter HeLa cells. Both PHD2 (the
main PHD enzyme responsible for prolyl hydroxylation of HIF1a)
and VHL were identified in the screen, validating our genetic
approach (Figures 1E and 1F). In addition, we identified twomito-
chondrial genes, OGDH and LIAS (Figures 1E–1G), which were
not only highly enriched for gene-trap insertions but whose
CRISPR-Cas9-mediated depletion stabilized the HIF1a-GFPODD
reporter in HeLa cells similarly to depletion of PHD2 and VHL
(Figure 1H). OGDH is the E1 component of the OGDHC that con-
verts 2-OG to succinate in the TCA cycle. As this complex re-
quires lipoylation (conjugation with lipoate, the conjugate base
of lipoic acid) within the mitochondria by LIAS on the E2 subunit
(dihydrolipoyl succinyltransferase [DLST]) for catalytic activity
(Figures 1G and S2B), we hypothesized that LIAS and OGDH
might regulate HIF1a through a common mechanism.
Depletion of OGDH and LIAS Leads to the Accumulation
of HIF1a in Aerobic Conditions
CRISPR-Cas9-targeted deletions of OGDH and LIAS in HeLa
cells confirmed that depletion of these genes not only stabilized
the GFP reporter but also increased endogenous HIF1a levels.
HIF1a-GFPODD reporter or wild-type HeLa cells were transduced
with lentiviral constructs encoding Cas9 and single guide RNAs
(sgRNAs) targeting OGDH or LIAS and HIF1a levels quantified by
immunoblot. Depletion of either LIAS or OGDH increased endog-
enous HIF1a levels in both wild-type and reporter cells (Figures
2A, S1H, and S1I). The increase in HIF1a was similar to levels
observed in cells depleted of PHD2 (Figures 2A and S1H). We
also found that depletion of OGDH or LIAS not only stabilized
HIF1a in KBM7 and HeLa cells, but also in primary human skin
fibroblasts (Figure 2B), suggesting that disruption of these genes
increased HIF1a levels through a common cellular mechanism.
FACS of the GFPLOW and GFPHIGH populations confirmed that
the increased GFP signal in the reporter cells was due to disrup-
tion of LIAS or OGDH, as only the cells deficient of these genes
were GFPHIGH in these mixed CRISPR-Cas9-targeted popula-
tions (Figures 2C and 2D). Furthermore, by overexpression of
OGDH and LIAS designed to be resistant to the relevant sgRNA,
we were able to prevent stabilization of HIF1a-GFPODD and
HIF1a upon CRISPR-Cas9 deletion of the endogenous alleles
(Figures S1J–S1O).
To determine whether depletion of OGDH or LIAS was associ-
ated with a HIF1 transcriptional response, we examined the sub-
cellular localization of HIF1a and measured the expression of
HIF1 target genes. Confocal immunofluorescence microscopy
confirmed that HIF1a accumulated in the nucleus of HeLa cells
depleted for OGDH or LIAS (Figure 2E). This nuclear stabilization
was associated with increased cell surface expression of the
target gene CA9 (Figure 2F) and the mRNA expression of the
HIF1 target genes, GLUT1 and VEGF (Figures 2G and 2H).
The genetic screen suggested that OGDH and LIAS might
regulate HIF1a levels through disruption of the OGDHC.742 Cell Metabolism 25, 740–752, November 8, 2016Although the E2 (DLST) and E3 (dihydrolipoamide [DLD]) sub-
units of the OGDHC were not identified in our screen (Figures
S2A and S2B), it is unlikely that these screens reach saturation.
We therefore asked whether depletion of these genes also
increased HIF1a levels and designed sgRNA to target the E2
and E3 subunits in HIF1a-GFPODD reporter and wild-type HeLa
cells. Depletion of either DLST or DLD induced the GFP reporter
and increased endogenous HIF1a levels (Figures S2C and S2D),
similarly to OGDH and LIAS depletion. Therefore, depletion of
any OGDHC component stabilizes HIF1a in aerobic conditions.
Depletion of OGDH or LIAS Prevents Prolyl
Hydroxylation of HIF1a
As the predominant mechanism for regulating HIF1a levels is
through prolyl hydroxylation, we examined whether this was dis-
ruptedwhenOGDHor LIASwere depleted. UsingHIF1a-specific
antibodies that distinguish between total and hydroxyprolyl
levels, we observed that both OGDH and LIAS depletion resulted
in the accumulation of HIF1a in a non-hydroxylated form (Fig-
ure 3A). Indeed, accumulation of non-hydroxylated HIF1a
following disruption of the OGDHC was similar to that seen in
cells depleted of PHD2 (Figure 3A). This is in marked contrast
to CRISPR-Cas9 depletion of VHL, which acts downstream of
prolyl hydroxylation, and therefore causes the accumulation of
hydroxylated HIF1a (Figure 3A). Furthermore, we observed no
decrease in PHD2 protein levels (Figure 3A), suggesting that
disruption of the OGDHC stabilized HIF1a by inhibiting PHD2 ac-
tivity rather than altering cellular levels of the enzyme.
We also isolated several knockout (KO) clones from the lenti-
viral CRISPR-Cas9-targeted populations. While prolonged cul-
ture of OGDH and LIAS CRISPR-Cas9-targeted cells did result
in increased cell death, we were able to isolate several OGDH
and LIAS null clones, which proliferated and could be passaged
similarly to PHD2 KO cells (Figure S3A). These OGDH and LIAS
clones still showed accumulation of HIF1a compared to controls
after several passages, albeit to a lesser extent than the PHD2
null clones (Figures S3A–S3C). It was also noteworthy that the
OGDH null clones had higher levels of HIF1a compared to the
LIAS null clones (Figures S3A–S3C). However, consistent with
results from the mixed CRISPR-targeted cells, HIF1a was accu-
mulated in a non-hydroxylated form (Figure S3C).
To directly measure prolyl hydroxylase activity following
disruption of the OGDHC, we established an in vitro assay (Fig-
ure 3B). Lysates from wild-type HeLa or mixed CRISPR-Cas9-
targeted populations for OGDH, LIAS, and PHD2were incubated
with a purified His-tagged HIF1aODD protein (Figure 3C) and hy-
droxylation measured using the hydroxyprolyl-specific antibody
at 0 and 15 min. The HIF1aODD protein was rapidly hydroxylated
in the wild-type lysate, but reduced hydroxylation of HIF1aODD
was observed in the OGDH-, LIAS-, and PHD2-depleted cell ex-
tracts (Figure S3D). Furthermore, in vitro hydroxylation of the
HIF1aODD protein was markedly reduced in all OGDH and LIAS
KO lysates compared to the control (Figures 3D and 3E). Thus,
disruption of theOGDHCor inhibition ofmitochondrial lipoylation
stabilized HIF1a by inhibiting PHD enzymatic activity.
Disruption of the OGDHC Drives the Formation of 2-HG
Small molecule metabolites can inhibit PHD activity in aerobic
conditions (Hewitson et al., 2007; Selak et al., 2005). To identify
Figure 2. Depletion of OGDH and LIAS Leads to the Accumulation of HIF1a in Aerobic Conditions
(A) CRISPR-Cas9 depletion of OGDH and LIAS in HeLa cells. HIF1a levels were measured by immunoblot. sgRNA to PHD2 was used as a control. Lipoate
antibody was used to detect lipoylation by LIAS. The lower band relates to DLST lipoylation (see Figure 1G), and higher band relates to PDH complex lipoylation.
The different lipoate species are detected with varying efficiency by the lipoate antibody.
(legend continued on next page)
Cell Metabolism 25, 740–752, November 8, 2016 743
Figure 3. Depletion of OGDH and LIAS Pre-
vents Prolyl Hydroxylation of HIF1a
(A) Immunoblots of total HIF1a and prolyl hydroxy-
HIF1a (OH-HIF1a) in HeLa HIF1a-GFPODD cells
transduced with lentiviral sgRNA to VHL, PHD2,
OGDH, and LIAS.
(B) Schematic of in vitro prolyl hydroxylation re-
action of HIF1aODD.
(C) Coomassie-stained gel of the recombinantly
expressed His-HIF1aODD protein.
(D and E) In vitro prolyl hydroxylation of the
HIF1aODD protein using lysates from PHD2, OGDH
(D), and LIAS (E) KO clones. See also Figure S3.the metabolic changes responsible for decreasing prolyl hydrox-
ylation of HIF1a, we measured metabolite levels in wild-type,
PHD2, OGDH, and LIAS null HeLa cells using liquid chromatog-
raphy-mass spectrometry (LC-MS) and 13C-glutamine isotope
labeling (Figure 4A). Levels of cellular metabolites in the PHD2
null clones were assessed to account for the metabolic changes
caused by HIF1 activation.
Principle component analysis demonstrated that OGDH and
LIAS depletion was associated with marked alterations in intra-
cellular metabolites, with low variation between each gene KO
(Figures S4A and S4B). This was in contrast to the PHD2 null
cells, which did not impact significantly on most cellular metab-
olites compared to the wild-type cells (Figures S4A and S4B),
indicating that activation of HIF1 was not responsible for the
metabolic changes seen following OGDH or LIAS depletion. Hi-
erarchical clustering highlighted the different metabolic profiles
of the OGDH and LIAS KO cells (Figure S4C), as depletion of
OGDH or LIAS impacted on distinct aspects of cellular meta-
bolism, particularly pyruvate metabolism. This was to be ex-(B) CRISPR-Cas9 depletion of OGDH and LIAS in primary adult human dermal fibroblasts. Cells were transd
OGDH or LIAS. After 17 days, the cells were lysed and immunoblotted for endogenous HIF1a, PHD2, OGDH
(C and D) HIF1a-GFPODD HeLa cells were transduced with Cas9 and sgRNA to PHD2, OGDH, or LIAS, sorted b
(C), and immunoblotted for endogenous HIF1a (D).
(E) Confocal immunofluorescence microscopy of HIF1a-GFPODD HeLa cells transduced with lentiviral sgRN
(F) Cell surface CA9 was measured by flow cytometry in HeLa cells (gray) depleted of OGDH or LIAS (blue)
(G and H) OGDH, LIAS, and PHD2 were depleted in HeLa cells using CRISPR/Cas9-targeted deletions. mRN
was extracted 14 days after lentiviral transduction, and Sybr Green (QIAGEN) qPCRwas used tomeasure them
and VEGF (H) (n = 4). Values are mean ± SEM. *p < 0.05. See also Figures S1 and S2.
744 Cell Metabolism 25, 740–752, November 8, 2016pected, as lipoate is also a cofactor for
the pyruvate dehydrogenase (PDH) com-
plex; thus, LIAS KO clones have elevated
levels of pyruvate and lactate compared
to the OGDH clones (Figures S5D–S5F).
The most striking alteration in both the
OGDH and LIAS KO clones compared
to wild-type cells was near-complete
disruption of the TCA cycle at the point
of the OGDHC, with accumulation of
2-OG, barely detectable levels of succi-
nate, and decreased levels of malate
(Figures 4B–4E). In support to this obser-
vation, we observed that 13C-glutamine
oxidation within the TCA cycle was
reduced (Figures 4F and 4G). The 13C-glutamine isotope labeling also demonstrated that deletion of
OGDH or LIAS promoted reductive metabolism, evidenced by
an increase in m+5 citrate, derived from m+5 2-OG (Figure 4F),
and m+3 malate, derived from m+5 citrate (Figure 4G). Reduced
mitochondrial function was also confirmed by themarked reduc-
tion in oxygen consumption rates seen in cells depleted of OGDH
or LIAS (Figures S5A–S5F).
The metabolic profile of the OGDH and LIAS null cells
suggested that PHD activity must be inhibited despite high
levels of 2-OG and low succinate. This was particularly
intriguing, as prior studies showed that mutations in other
TCA cycle enzymes inhibit PHD activity through the accumula-
tion of TCA intermediates such as succinate (Selak et al., 2005).
We therefore sought other mechanisms for regulating PHD
activity. We excluded a major role of mitochondrial reactive ox-
ygen species (ROS), as we only observed a small increase in
ROS following OGDH or LIAS depletion using the MitoSOX
Red mitochondrial superoxide indicator, which was unlikely to
be sufficient to stabilize HIF1a (Figures S5G and S5H), anduced with lentivirus encoding Cas9 and sgRNA to
, or lipoate.
y FACS into low (Lo) and high (Hi) GFP populations
A to OGDH and LIAS.
as described.
A from these mixed CRISPR targeted populations
RNA levels of HIF1a or its target genes, GLUT1 (G)
Figure 4. Changes in Cellular Metabolism following Depletion of OGDH or LIAS
(A) Schematic of the TCA cycle (black arrows) and reductive metabolism (blue arrows) indicating the number of labeled carbons (green) derived from
13C-glutamine. The position of the OGDHC is highlighted.
(B–E) Relative intracellular abundance of key metabolites involved in the TCA cycle.
(F and G) Isotopologue abundance of m+4 and m+5 citrate (F), and m+4 and m+3 malate (G), measured by 13C-glutamine isotope labeling and expressed as a
percentage of the total metabolite level. The number of labeled carbons (green) is indicated. n = 5. **p < 0.01 WT compared to KO clones, ***p < 0.01 OGDH
compared to LIAS null clones. ND, not detected. See also Figures S4 and S5.instead focused on shared metabolic consequences of deleting
these genes.
One metabolite that significantly accumulated in both OGDH
and LIAS KO clones compared to the controls was 2-hydroxy-
glutarate (2-HG) (Figures 5A and 5B), a chiral compound derived
from 2-OG (Figures 5C and 5D) that can inhibit 2-OG dioxyge-
nases (Chowdhury et al., 2011; Koivunen et al., 2012; Tarhon-
skaya et al., 2014b). In support of this finding, we observed
decreased activity of the TET 2-OG-dependent dioxygenases
(which are inhibited by cellular accumulation of 2-HG [Xu et al.,
2011]) by measuring the levels 5-hydroxymethylcytosine
(5hmC) in the OGDH- or LIAS-deficient cells (Figures S6A–S6D).While both L and D enantiomers of 2-HG can be formed in
cells, there are conflicting reports as to whether these com-
pounds inhibit or activate PHDs. In vitro studies suggest
that L-2-HG is a potential inhibitor of PHD enzymatic activity
(Chowdhury et al., 2011), although this has not been shown in
cells. D-2-HG, which is mainly formed by mutations in isocitrate
dehydrogenase (IDH) (Dang et al., 2009), has been reported to
both inhibit and activate prolyl hydroxylase enzymes (Koivunen
et al., 2012). We used chiral derivatization to distinguish between
the L and D-2-HG enantiomers prior to analysis by LC-MS/MS
and observed that while both L-2-HG and D-2-HG levels were
increased in OGDH null clones compared to WT and PHD2 KOCell Metabolism 25, 740–752, November 8, 2016 745
Figure 5. Disruption of the OGDHC Pro-
motes the Formation of 2-HG
(A) Schematic of the formation of 2-HG from
2-OG, indicating the number of labeled carbons
expected (green) when m+5 2-OG is directly
converted to m+5 2-HG following 13C-glutamine
labeling.
(B) Intracellular abundance of 2-HG in the wild-
type, KO OGDH, and KO LIAS HeLa clones.
(C and D) Levels of m+0 and m+5 2-OG (C) and
2-HG (D) isotopologues measured by 13C-gluta-
mine isotope labeling. Five independent cell cul-
tures were measured for each KO clone, and
two KO clones were used for each gene. **p < 0.01
WT compared to KO clones, ***p < 0.01 OGDH
compared to LIAS null clones.
(E and F) In vitro assaymeasuring the effect of L- or
D-2-HG on prolyl hydroxylation of the HIF1aODD.
Recombinant pure HIF1aODD protein was incu-
bated with HeLa cell extracts for 0 or 15 min at
37C, with or without the addition of increasing
concentrations of L-2-HG (left) or D-2-HG
(right) (0.5–10 mM). Hydroxylation of HIF1aODD
was measured using the hydroxyprolyl-specific
antibody (E) and compared to total levels of the
HIF1aODD protein (F), n = 3. Values are mean ±
SEM. *p < 0.05 (L-2-HG treatment compared to
control). See also Figure S6.cells, there was a 10-fold increase in L-2-HG levels, with only a
4-fold change in D-2-HG levels (see Figure S6G). Of note, quan-
tification of 2-HG indicated that this metabolite reaches 0.67mM
(±0.24) in OGDH-deficient cells (Table S1), which is in the region
of the IC50 for inhibition of PHD by L-2-HG (Chowdhury et al.,
2011).
To test whether the 2-HG enantiomers were able to inhibit
PHD activity in our experimental model, we measured prolyl
hydroxylation of HIF1aODD in HeLa cell extracts treated with
increasing concentrations of L- or D-2-HG (Figures 5E and 5F).
Hydroxylation of HIF1aODD was inhibited with increasing con-
centrations of L-2-HG, but the addition of D-2-HG had no effect
on the hydroxylation of the HIF1aODD protein (Figures 5E and 5F).746 Cell Metabolism 25, 740–752, November 8, 2016Thus, L-2-HGwas the predominant enan-
tiomer formed when the OGDHCwas dis-
rupted and only L-2-HG had the ability to
prevent prolyl hydroxylation of HIF1a.
Decreasing L-2-HG Levels
Restores HIF1a Turnover when
2-OG Accumulates or OGDHC
Activity Is Impaired
Because L-2-HG is formed from 2-OG by
spurious activity of lactate dehydroge-
nase A (LDHA) and the malate dehyodro-
genases (MDH1 and MDH2) (Intlekofer
et al., 2015; Oldham et al., 2015), deple-
tion of these enzymes should restore
PHD function in the OGDH- or LIAS-defi-
cient cells. We therefore depleted LHDA,
MDH1, and MDH2 in the OGDH and LIAS
KO clones and measured endogenousHIF1a levels (Figures 6A–6D). Depletion of LDHA, MDH1, or
MDH2 all restored HIF1a turnover (Figures 6A–6D). Treating
OGDH- or LIAS-deficient cells with the LDHA inhibitor oxa-
mate also restored HIF1a turnover (Figures S6E and S6F) and
prevented the accumulation of L-2-HG in OGDH null cells
(Figure S6G). Furthermore, we also found that promoting the
conversion of L-2-HG to 2-OG by overexpressing the specific
L-2-HG dehydrogenase (L-2-HGDH) decreased HIF1a levels in
the OGDH KO cells (Figure 6E). Thus, L-2-HG is responsible
for the reversible inhibition prolyl hydroxylation of HIF1a.
To determine whether high intracellular levels of 2-OG were
sufficient to promote PHD inhibition in aerobic conditions,
we examined whether cell-permeable 2-OG stabilized HIF1a.
Figure 6. Decreasing L-2-HG Levels Restores HIF1a Turnover when 2-OG Accumulates or OGDHC Activity Is Impaired
(A–C) siRNA-mediated depletion of LDHA (A), MDH1 (B), or MDH2 (C) in wild-type HeLa, OGDH null, and PHD2 null clones. siRNA were transfected into OGDH or
PHD KO cells and HIF1a levels measured by immunoblot after 72 hr (A–C, top). Densitometry analysis of HIF1a levels (A–C, bottom) (n = 3).
(D) siRNA-mediated depletion of LDHA, MDH1, or MDH2 in LIAS null clones.
(E) HIF1a levels in OGDH KO clones transduced with or without L-2-HGDH. HIF1a and L-2-HGDH levels visualized by immunoblot.
(legend continued on next page)
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Wild-type and HIF1a-GFPODD reporter HeLa cells were treated
with a cell-permeable 2-OG analog, dimethyl 2-OG (DM2-OG),
for 24 hr. HIF1a levels were measured by stabilization of the
reporter or by immunoblot, and 2-HG levels by mass spec-
trometry. DM2-OG treatment increased 2-HG levels in cells
from approximately 0.15 mM to 1 mM (Table S1) and stabilized
endogenous HIF1a (Figures S6H and S6I) similarly to levels
observed with disruption of OGDHC activity. Moreover, HIF1a
levels were reversed to near-basal levels following treatment
with the LDHA inhibitor oxamate (Figures 6F and 6G). To confirm
that HIF1a stabilization was dependent on L-2-HG formation, we
overexpressed the enantiomer-specific 2-HG dehydrogenases
(L-2-HGDH and D-2-HGDH) in wild-type and HeLa reporter cells
treated the cells with DM2-OG. Cells overexpressing L-2-HGDH
had reproducibly less HIF1a stabilization compared to wild-type
and controls and those expressing D-2-HG (Figures 6H–6J).
Together, these experiments show that the accumulation of
2-OG in aerobic conditions is sufficient to promote the formation
of L-2-HG, inhibit PHD activity, and stabilize HIF1a.
Human Homozygous Germline Mutations in
Mitochondrial Lipoylation Stabilize HIF1a
To explore the physiological relevance of 2-OG accumulation in
aerobic conditions, we focused on several recently described
rare inborn errors of metabolism in lipoic acid synthesis. Children
with these mutations present with variant non-ketotic hypergly-
cinaemia (vNKH), a form of Leigh’s syndrome, characterized by
severe neurological defects, lactic acidosis, and raised 2-OG
and glycine levels (Baker et al., 2014; Mayr et al., 2011). As lip-
oate is only formed within the mitochondria by LIAS in eukaryotic
cells, supplementation with exogenous lipoic acid is not suffi-
cient to treat vNKH and the affected individuals due at a young
age (Baker et al., 2014). Interestingly, although the predominant
characteristics of vNKH relate to altered metabolism, several
features would be in keeping with HIF1 activation, including
angiogenesis in the neurological lesions, cardiomyopathies,
and the development of pulmonary hypertension (Ahting et al.,
2015).
We obtained skin fibroblasts from four vNKH patients with
previously described or causative homozygous mutations in
different genes involved in lipoic acid synthesis: LIAS, NFU1
(NFU1 Iron-Sulfur Cluster Scaffold), ISCA2 (Iron-Sulfur Cluster
Assembly 2), and BOLA3 (BolA Family Member 3) (Figure 7A)
(Ahting et al., 2015; Haack et al., 2013; Mayr et al., 2011). LIAS
incorporates an iron-sulfur (4Fe-4S) cluster for catalytic activity,
and it has recently been shown that mutations in Fe-S biogenesis
genes (BOLA3, NFU1, and ISCA2) reduce lipoate formation and
result in vNKH (Baker et al., 2014). Homozygous mutations in
LIAS, BOLA3, and NFU1 not only showed marked defects in lip-
oylation compared to control fibroblasts (Figure 7B), but also had
reduced OCRs (Figure S7A), similarly to rates observed following
LIAS depletion in HeLa cells (Figures S5A–S5F). Mitochondrial
lipoylation was still detected in the mutant ISCA2 cells, which(F andG) HIF1a-GFPODD reporter (F) or wild-type (G) HeLa cells were treatedwith 4
for 24 hr. HIF1a levels were measured by GFP levels (F) or by immunoblot (G).
(H and I) HIF1a-GFPODD reporter HeLa cells overexpressing L-2-HDGH or D-2-HG
levels (H) or by immunoblot (I). Quantification ofmean change inGFP levels is show
also Figure S6.
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homozygous mutations in ISCA2 result in a milder phenotype.
However, all homozygous mutations in lipoic acid synthesis
demonstrated higher levels of HIF1a compared to control fibro-
blasts (Figures 7C and 7D). This increase in HIF1a was associ-
ated with an increase in mRNA expression of GLUT1, without
significant changes in HIF1a transcript levels (Figures S7B and
S7C), consistent with defective lipoylation inhibiting PHD activity
under aerobic conditions. Moreover, 5hmC levels were reduced
by approximately 50% in the LIAS R249H fibroblasts compared
to controls (Figures 7E and 7F), consistent with defects in lipoy-
lation also affecting the TET 2-OG-dependent dioxygenases.
To determine whether L-2-HG derived from 2-OG was
responsible for stabilizing HIF1a in the lipoate-deficient cells,
we measured intracellular metabolite abundance in the control
and mutant LIAS fibroblasts. Levels of 2-OG and 2-HG were
increased in the LIAS R249H mutant fibroblasts compared to
the controls (Figures 7G and 7H). Furthermore, we observed a
general decrease in the levels of TCA intermediates consistent
with a reduction in oxidative metabolism (Figures S7D and
S7E), which were similar to the metabolite changes seen in the
HeLa LIAS null clones (Figure 4). In addition, 2-HG levels ap-
peared to correlate with the degree of HIF1a stabilization
observed in the LIAS mutant fibroblasts compared to the HeLa
LIAS or OGDH KOs, with 2-HG and HIF1a levels highest in the
OGDH KO clones (Figure 5B).
We next examined whether decreasing L-2-HG formation
restored HIF1a turnover. Mutant LIAS R249H or control fibro-
blasts were treated with 40 mM oxamate for 24 hr and
HIF1a levels measured by immunoblot. LDHA inhibition repro-
ducibly decreased HIF1a levels in the LIAS R249H fibroblasts
compared to the controls (Figures 7I and 7J). Similar findings
were observed with oxamate treatment of the BOLA3, NFU1,
and ISCA2 mutant fibroblasts (Figure S7F), consistent with
LDHA inhibition restoring HIF1a turnover. We also examined
whether oxamate was able to restore HIF1a turnover in the
LIAS mutant cells at lower oxygen tensions. Control or LIAS
R249H fibroblasts were incubated in 6% oxygen and treated
with oxamate for 24 hr. While HIF1a levels were still reduced in
the oxamate-treated LIAS R249H fibroblasts at 6% oxygen, we
now observed that oxamate treatment also decreased the levels
of HIF1a in the control cells (Figure S7G), supporting the notion
that 2-OG and L-2-HG levels may contribute to the homeostatic
regulation of PHD activity. Thus collectively, these data confirm a
role for mitochondrial enzyme lipoylation and the OGDHC in
regulating prolyl hydroxylation of HIF1a through the formation
of L-2-HG (Figures 7K and 7L).
DISCUSSION
Using an unbiased forward genetic approach, we identify that
the OGDHC is central to the regulation of PHD activity in aerobic
conditions. This was unexpected, as intracellular accumulationmMDM2-OGor 0.5mMDMOGwith or without the addition of 40mMoxamate
DH were treated with DM2-OG for 24 hr. HIF1a levels were measured by GFP
n (I, right) (n = 4). Values aremean ± SEM. *p < 0.05. **p < 0.01. ***p < 0.001. See
Figure 7. Human Germline Mutations in
Mitochondrial Lipoylation Stabilize HIF1a
(A) Structural modeling of mutations in the Fe-S
cluster biogenesis genes (BOLA3, NFU1, and
ISCA2) and LIAS. Germline homozygous mutated
residues are indicated, and Fe-S binding sites are
highlighted.
(B–D) Levels of HIF1a and lipoylation in skin fi-
broblasts from patients with mutations in proteins
required for lipoic acid synthesis. Lipoate and
total HIF1a levels were analyzed by immunoblot.
HIF1a levels were also quantified from four sepa-
rate experiments by densitometry analysis (D).
Different isoforms of HIF1a are likely to account for
the small changes in HIF1a migration observed in
patient fibroblast lines (C).
(E and F) TET enzyme activity in control or LIAS
R249H mutant fibroblasts. Total genomic DNA
levels were measured by methylene blue staining,
and the relative levels of 5hmC quantified by
densitometry (F) (n = 4).
(G and H) Relative intracellular abundance of
2-OG (G) and 2-HG (H), in control and LIAS
R249H mutant fibroblasts measured by LC-MS as
described. (n = 5).
(I and J) Oxamate treatment prevents HIF1a
accumulation in LIAS mutant fibroblasts. Control
or LIAS R249H fibroblasts were treated with
40 mM oxamate for 24 hr and HIF1a levels
measured by immunoblot (I). Fibroblasts from two
unrelated patients were used as controls (Ct1 and
Ct2). Quantification of HIF1a levels from three
separate experiments is shown in (J). *p < 0.05,
**p < 0.01, ***p < 0.001.
(K and L) Model for the mechanism of HIF1a sta-
bilization following disruption of the OGDHC by
depletion of OGDH or decreased mitochondrial
lipoylation. In resting cells, 2-OG is mainly utilized
in oxidative metabolism and HIF1a is hydroxyl-
ated by PHD2, driving its rapid ubiquitination
and proteasomal degradation (K). When OGDHC
activity is reduced, the accumulation of 2-OG
drives reductive metabolism and the formation of
L-2-HG, which inhibits PHD activity, thereby sta-
bilizing HIF1a in aerobic conditions (L). See also
Figure S7.of 2-OG was unlikely to inhibit PHD activity, and prior reports
show that cell-permeable 2-OG can overcome succinate-medi-
ated inhibition of HIF1a prolyl hydroxylation (MacKenzie et al.,
2007). Instead, we uncover that PHD activity is inhibited when
2-OG accumulates, through the formation of L-2-HG. The bio-
logical implications of these findings are diverse, as disrupting
the OGDHC itself, or genes involved in Fe-S and lipoate bio-
synthesis, all stabilize HIF1a through the same mechanism.
Although 2-HG is increasingly recognized as a major metabolic
regulator in tumors (Kaelin, 2011), the relative importance of
this molecule in regulating PHDs was controversial, particularly
as it was thought that 2-HG is unlikely to inhibit PHD activity
without a concurrent decrease in 2-OG levels (Xu et al., 2011).
We now show that L-2-HG is not only able to inhibit PHD2, but
is also derived from accumulated 2-OG within cells in aerobicconditions. These findings are consistent with the formation of
L-2-HG from 2-OG in hypoxia (Intlekofer et al., 2015; Oldham
et al., 2015) and suggest a more general role for 2-OG meta-
bolism in regulating prolyl hydroxylases.
Our metabolic and biochemical studies show that L-2-HG is
the predominant enantiomer formed when the OGHC is disrup-
ted. Moreover, prolyl hydroxylation of HIF1a was only inhibited
by L-2-HG and not D-2-HG, consistent with prior reports
(Chowdhury et al., 2011). Whether D-2-HG can activate HIF1a
(Koivunen et al., 2012) is unclear from our studies. Although we
observed a small increase in hydroxylation of the HIF1a protein
following the addition of D-2-HG, Tarhonskaya et al. show that
this increase is due to non-enzymatic oxidation of 2-HG when
iron and reducing agents are added to the reaction (Tarhonskaya
et al., 2014a). It is noteworthy that exogenous iron and ascorbateCell Metabolism 25, 740–752, November 8, 2016 749
were not required for our in vitro assay. Irrespective of these find-
ings, the dominant effect observed in our experiments seems to
be PHD inhibition by L-2-HG when OGDHC activity is reduced.
We observed that oxamate decreased HIF1a levels in primary
fibroblasts incubated in 6% oxygen, a concentration represen-
tative of physiological oxygen levels in tissues. It is therefore
possible that L-2-HG formation may serve a homeostatic role
in regulating PHD activity in both aerobic and anaerobic condi-
tions. Indeed, further support for a feedback loop is suggested
by the ability of HIF1a to promote the proteasome-mediated
degradation of a short OGDH isoform (OGDH2) and decrease
OGDHC activity (Sun and Denko, 2014). Although we observed
lower levels of the major OGDH isoform in PHD2 null cells and
decreased mitochondrial lipoylation (Figure 2D), we did not
find any significant alterations in OGDHC complex activity or
2-OG levels in the PHD2 KO cells compared to wild-type HeLa
cells (Figure S6). It will be of interest in further studies to deter-
mine the relative importance of this potential feedback mecha-
nism in physiological contexts.
The finding that HIF1a is elevated in patient cells with homozy-
gous mutations in lipoic acid synthesis highlights the potential
role of this transcription factor in these conditions. Indeed, a
recent genome-wide screen identifies hypoxia and VHL inhi-
bition as a potential therapy for mitochondrial diseases pre-
senting with Leigh syndrome (Jain et al., 2016). It is therefore
possible that HIF1 activation serves as a protective physiological
response in patients with defective lipoic acid synthesis. Homo-
zygous mutations in lipoic acid synthesis are rare, and mostly le-
thal at a young age, therefore certain features associated with
HIF1 activation, such as tumor formation, may not be expected.
Moreover, although the patients did not have an erythrocytosis,
the occurrence of vascular proliferation in the neurological le-
sions and the development of pulmonary hypertension in some
of the patients with lipoate deficiency is intriguing and warrants
further investigation.
Heterozygous germline mutations in genes involved in lipoic
acid synthesis or the OGDHC have not been characterized, but
it is in these patients that loss of heterozygosity may promote
tumor formation as has been shown for heterozygous mutations
in the TCA cycle enzymes succinate dehydrogenase (SDH) and
fumarate hydratase (FH) (Pollard et al., 2007; Selak et al.,
2005). Indeed, while the tumorigenic role of 2-OG-dependent
dioxygenases is debated, it will be of interest to determine
whether OGDHC activity and lipoate formation influence the
enzymatic activity of other 2-OG-dependent dioxygenases, simi-
larly to the PHDs and TET enzymes shown here. Indeed, several
somatic mutations in LIAS or OGDH have been collated (Cata-
logue of Somatic Mutations in Cancer [COSMIC] database)
(Forbes et al., 2010), and a number of the LIAS mutations are
similar to the known homozygous mutations, which tend to
occur around the Fe-S cluster coordination sites. Whether these
mutations promote HIF1 stabilization, histone modification, and
tumor formation will be important to address in future studies.EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
KBM7 cells were maintained in Iscove’s Modified Dulbecco’s Medium (IMDM,
GIBCO) supplemented with 10% fetal calf serum (FCS) and 1% penicillin/750 Cell Metabolism 25, 740–752, November 8, 2016streptomycin. HeLa andHEK293ET cells weremaintained in Dulbecco’sModi-
fied Eagle’s Medium (DMEM, GIBCO) supplemented with 10% FCS. Primary
skin fibroblasts were also cultured in DMEM, but supplemented with 20%
FCS. Fibroblast cell lines from patients with homozygous mutations in lipoic
acid synthesis are detailed in Supplemental Information. Hypoxic cell culture
was performed in a Whitley H35 Hypoxystation (Don Whitley Scientific) at
37C/5% CO2 plus either 1% O2/94% N2 or 6% O2/89% N2.
A complete list of plasmids, reagents, and antibodies used are detailed in
Supplemental Information.
Lentiviral/Retroviral Production and Transduction
Lentivirus was produced by triple-transfection of HEK293ET cells with the
appropriate lentiviral transgene vector and the packaging vectors pCMVR8.91
(gag/pol) andpMD.G (VSVG).TransfectionwasperformedusingTrans-IT293re-
agent (Mirus) with cells at 70%–80% confluency in 6-well plates. Viral superna-
tantwas harvested at 48 hr, filtered through a 0.45 mmfilter, and frozen at80C
until required. For transduction, cells were seeded to 24-well plates in 500 mL
culture medium. 500 mL viral supernatant was added to each well and plates
centrifugedat1,800 rpm,37C for1hr.Plateswere then incubated for 3hrbefore
an additional 1 mL fresh mediumwas added to each well. Cells were expanded
andantibiotic selectionapplied from48hr if required. TheZ-loxP-mCherrygene-
trap retrovirus was produced as for the lentivirus supernatants but with the
appropriate packaging vectors (pMD.Gag.Pol and pMD.VSVG).
Flow Cytometry
23 105 cells per sample were washed in 3mL ice-cold PBS in 5mL round-bot-
tom polystyrene tubes and resuspended in 200 mL PBS/1% formaldehyde
prior to analysis on a FACScalibur (GFP, AF488, PI, AF647) or BD Fortessa
(GFP, AF488, mCherry, AF568, AF647). For cell-surface staining, cells were
washed in 3 mL ice-cold PBS, resuspended, and incubated at 4C for
30 min with the primary antibody. Samples were then washed with PBS and
incubated with an appropriate secondary antibody at 4C for 30 min.
Forward Genetic Screen in Near Haploid KBM7 Cells
The KBM7 forward genetic screen was carried out as described by Tchasov-
nikarova et al. (2015), with some modifications. 1 3 108 clonal KBM7 cells
expressing the HIF1a-GFPODD reporter were transduced with the retroviral
Z-loxP-mCherry gene-trap supernatant plus 10 mg/mL hexadimethrine bro-
mide (Polybrene) at 1,800 rpm (37C) for 1 hr. Cells were then incubated for
3 hr at 37C before the addition of 500 mL fresh IMDM. Transduction efficiency
was measured by flow cytometry after 72 hr.
Cells were enriched for mutagenized GFPHIGH cells by one round of FACS at
day 8. 24 hr prior to sorting the cells were purified by centrifugation for 20 min
at 1,800 rpm on a Lympholyte cell separation density gradient (Cedarlane
Labs) to remove debris. The cells were then resuspended in PBS supple-
mented with 2% FCS and 10 mM HEPES for sorting. Selected cells were
collected into IMDM with 50% FCS and 10 mM HEPES. Cells were expanded
for 4 days prior to lysis. Gene-trap integration sites were identified using a
PCR-based protocol as described by Tchasovnikarova et al. (2015).
CRISPR-Cas9-Targeted Deletions
Gene-specific CRISPR sgRNA sequences were selected from the GeCKO v2
library (Sanjana et al., 2014) and used to generate sense and antisense oligo-
nucleotides, with 50 CACC and 30 CAAA overhangs respectively. These sgRNA
were ligated into the LentiCRISPRv2 vector according to published methods
(Sanjana et al., 2014). An additional guanosine base was included in some
cases at the beginning of the sgRNA sequence to improve transcription from
the U6 promoter. CRISPR lentivirus production and transduction were
performed as described. Transduced cells were selected by puromycin treat-
ment. CRISPR-transduced cells were generally cultured for 9–10 days prior to
subsequent experiments to allow sufficient time for depletion of the target
protein. KO clones were isolated from the sgRNA-targeted populations by
serial dilution cloning and immunoblot. The full list of sgRNAs used is detailed
in the Supplemental Information.
Metabolomic Analyses
HeLa cells were seeded to 6-well plates at 3.5 3 105 cells per well in DMEM
24 hr prior to harvesting. For carbon flux analysis, the cells were cultured in
glutamine-free DMEM supplemented with 10% FCS and 4 mM 13C5 L-gluta-
mine (Cambridge Isotope Laboratories) for 24 hr. Metabolites were extracted
by washing the cells in ice-cold PBS before adding extraction buffer (50%
methanol, 30% acetonitrile, 20% H2O, 100 ng/mL HEPES) and incubating
the plates for 15min over dry ice andmethanol. The cells were then transferred
to 1.5 mL Eppendorf tubes and incubated on dry ice for 5 min. Tubes were
transferred to a thermomixer at 4C and shaken at 1,400 rpm for 15 min before
centrifuging at 14,000 rpm, 4C for 10 min. Finally, the supernatants were
transferred into autosampler vials and stored at80Cprior to Liquid Chroma-
tography Mass Spectrometry (LC-MS) analysis (detailed in the Supplemental
Information).
Immunoblotting
Cells were lysed in an SDS lysis buffer (1% SDS, 50 mM Tris [pH 7.4], 150 mM
NaCl, 10% glycerol, and 5 mL/mL Benzonase nuclease) for 10 min before
heating at 70C for 10min. Proteinswere separated by SDS-PAGE, transferred
to PVDF membranes, probed with appropriate primary and secondary anti-
bodies, and developed using SuperSignal West Pico or Dura Chemilumines-
cent Substrates (Thermo Scientific).
5hmC DNA Dot Blotting
Genomic DNAwas extracted from cultured cells using the Gentra Puregene kit
(QIAGEN). Genomic DNA dot blotting for 5hmC levels was performed as pre-
viously described (Szulwach et al., 2011) with some modifications. Briefly, the
genomic DNAwas denatured in 10mMEDTA 0.4MNaOH at 100C for 10min.
2-fold dilutions of denatured DNA were spotted onto Hybond NX membranes
(GE Healthcare), allowed to dry, and rinsed with 23 SCC buffer. The DNA was
UV crosslinked to the membrane, blocked with 1% BSA and 5%milk powder,
and probed for 5hmCwith a rabbit polyclonal antibody (Active Motif). The total
DNA levels were quantified by methylene blue staining, and relative densitom-
etry measured using ImageJ.
Immunofluorescence
HeLa cells were plated on glass coverslips overnight prior to staining. Media
was removed by three PBS washes prior fixation with PBS/4% formaldehyde.
Cells were permeabilized with 0.3% Triton X-100 and then blocked with 3%
BSA. Primary and secondary antibodies were incubated at desired con-
centrations, before three final washes and mounting to microscope slides
using ProLong Gold antifade with DAPI. Imaging was performed on a Zeiss
LSM880 confocal microscope.
qPCR
Total RNA was extracted using the RNeasy Plus minikit (QIAGEN) following
manufacturer’s instructions and then reversed transcribed using Super RT
reverse transcriptase (HT Biotechnology). PCR was performed on the ABI
7900HT Real-Time PCR system (Applied Biosystems) using SYBR Green
Master mix (Applied Biosystems). Reactions were performed with 125 ng of
template cDNA. Transcript levels of genes were normalized to a reference
index of housekeeping genes (GAPDH and RPS2).
In Vitro Hydroxylation Assay
To formtheHIF1aODDprotein,weexpressedaHis-taggedproteincorresponding
to residues 530–652 of human HIF1a in BL21 E. Coli and purified using a NiNTA
column on an A¨kta Pure FPLC (GE Healthcare). Protein purity was assessed by
SDS-PAGEandCoomassie staining, and theHIF1aODDproteinwasdialyzed into
20 mM Tris (pH 7.4), 150 mM NaCl with 1 mM DTT. The HeLa cell extract was
prepared from 1 3 108 cells lysed in 2 mL reaction buffer (RB: 20 mM HEPES
[pH 7.5], 5mM KCl, 1.5 mM MgCl2) followed by two cycles of freeze/thaw in an
ethanol/dry ice bath. The lysateswere passed eight times through a 21Gneedle,
followed by two passes through a 26G needle before centrifugation (17,0003 g
4C,30min). The supernatantswerealiquotedandstoredat80C.Thehydrox-
ylation assaywas performedby incubating 10mMHIF1aODDwith 50mLHeLacell
extract in RB for 15 min at 37C. The reaction was stopped by addition of SDS
loading buffer, and the proteins separated by SDS-PAGE. Hydroxylation was
measured using the HIF prolyl hydroxylation specific antibody. Measurements
of DMOG and 2-HG inhibition of HIF1a hydroxylation were performed similarly,
except the lysate was pre-incubated with the compounds for 10 min at 37C
before the addition of the HIF1aODD protein.siRNA-Mediated Depletion
siRNA SMARTpools for LDHA, MDH1 or MDH2 (Dharmacon) were transfected
into HeLa cells using Oligofectamine Transfection Reagent (Invitrogen) ac-
cording to the manufacturer’s protocol. Cells were harvested after 72 hr for
further analysis by immunoblot.
Statistical Analyses
Data were expressed as mean ± SEM and p values were calculated using
two-tailed Student’s t test for pairwise comparisons, unless otherwise stated.
Except for metabolomic experiments, no randomization or blinding was per-
formed. No statistical method or power analysis was used to predetermine
sample size.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2016.09.015.
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